|
Orchard Therapeutics Plc (NASDAQ: ORTX) |
|
Orchard Therapeutics Plc
ORTX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Orchard Therapeutics Plc growth rates, revenue grew
by 9.09 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 1329
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -8 %
Orchard Therapeutics Plc net loss decreased from $-48 millions, to $-35 millions in III. Quarter 2023,
• More on ORTX's Growth
|
|
Orchard Therapeutics Plc realized a net loss in trailing twelve months.
Orchard Therapeutics Plc realized cash reduction of $ -0.25 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 174.65.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.63.
• More on ORTX's Valuation
|
|
|
|
|
Orchard Therapeutics Plc realized net loss in trailing twelve months.
Orchard Therapeutics Plc realized cash outflow of $ -0.25per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 174.65.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.63.
Orchard Therapeutics Plc Price to Book Ratio is at 47.52 lower than Industry Avg. of 1412.52. and higher than S&P 500 Avg. of 0.01
• More on ORTX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com